Gingko acquisition Zymergen’s problems were evident to board shortly after IPO, SEC filings show

Details of Zymergen’s rise and fall emerged in a document filed Friday by Boston-based Gingko Bioworks, which is in the process of acquiring the California biotech in an all-stock deal valued at $300 million.